Stakeholder Opinions: Tropical Diseases – Dengue, Japanese Encephalitis And West Nile Virus Incr

.tags
Introduction

Dengue, Japanese encephalitis and West Nile virus are major causes of disease worldwide. Dual market pricing strategies for endemic countries and the Western travelers market offer great commercial opportunities for dengue and Japanese encephalitis vaccines. In contrast, low incidence makes West Nile a less commercially attractive target.

Scope of this research

Discussion of market environment for dengue, Japanese encephalitis and West Nile in US, 5EU and Japan, as well as the rest of the world Thorough assessments of key marketed vaccines and therapeutics, as well as pipeline products Epidemiology section discussing key epidemiological features of disease caused by dengue, Japanese encephalitis and West Nile Detailed background information on dengue, Japanese encephalitis and West Nile, including diagnostics, disease burden and potential drug targets Research and analysis highlights
Although a high disease burden and the spread of dengue make vaccination attractive in selected target groups, uptake in the 7MM will remain limited due to a lack of reimbursement structures.

The JE vaccine SA-14-14-2 (Chengdu) remains the first choice vaccine in many endemic regions. In the US and Europe, Intercells Ixiaro is now the preferred vaccine for military personnel and travelers. However, a low risk for travelers and out-of-pocket payment for travelers vaccines will limit its commercial potential in the 7MM.

Although West Nile virus has become endemic in the US and several European countries in the last decade, low overall incidence is a big obstacle for the development of antivirals and vaccines, as it complicates clinical trial design and limits commercial prospects.

Key reasons to purchase this research

Review vaccine and antiviral development progress, pipelines and success factors in dengue, JE and West Nile Understand challenges, unmet needs and future opportunities by learning about the views of industry and academic key opinion leaders Understand the epidemiology of dengue, Japanese encephalitis and West Nile virus in the seven major markets and its impact on commercial opportunities

Table of Contents :
Overview 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Infectious Disease pharmaceutical analysis team 2
Executive Summary 3
Scope of the analysis 3
Datamonitor insight into the dengue, Japanese encephalitis and West Nile vaccine/therapeutics market 3
Related reports 5
Upcoming reports 5
Table of Contents 6
1. Overview 8
Key findings 8
Background 8
Epidemiological trends 13
Disease management 15
Pipeline 17
Outlook 22
2. Dengue 25
Key findings 25
Disease background 25
Epidemiology 38
Market overview 45
Unmet needs 46
Dengue therapeutics pipeline 47
Dengue vaccines pipeline 50
Outlook 80
3. Japanese Encephalitis 85
Key findings 85
Disease background 85
Epidemiology 96
Market overview 101
Unmet needs 118
Japanese encephalitis therapeutics pipeline 120
Japanese encephalitis vaccines pipeline 120
Outlook for Japanese encephalitis 130
4. West Nile 133
Key findings 133
Disease background 133
Epidemiology 140
Market overview 146
Unmet needs 148
West Nile virus therapeutic pipeline 150
West Nile virus vaccine pipeline 157
Outlook for West Nile virus 164
5. Bibliography 168
Literature 168
Appendix 200
Contributing experts 200
Conferences attended 200
Report methodology 200
About Datamonitor 201

For some-more information, Great fully visit:

http://www.aarkstore.com/reports/Stakeholder-Opinions-Tropical-Diseases-Dengue-Japanese-encephalitis-and-West-Nile-virus-Increasing-attention-for-neglected-diseases-88067.html